ResearcherInha UniversityNo recent work listed
Jung Hee Park
Matched on ORCID iD 0000-0001-5577-1273; OpenAlex author ID A5041201250. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper
Papers 7
- Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. Co-author DOI 10.4062/biomolther.2021.145↗
- Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. Co-author DOI 10.1016/j.canlet.2021.03.015↗
- A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.03.041↗
- KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.09.013↗
- Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. Co-author DOI 10.1159/000491058↗
- Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Co-author DOI 10.18632/oncotarget.22850↗
- HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.12871↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zhenghuan Fang · 7 shared papers, 2016–2022 · strength 0.58
- Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
- Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
- Paper Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. DOI 10.1159/000491058↗
- Hong Hua Yan · 7 shared papers, 2016–2022 · strength 0.58
- Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
- Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
- Paper Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. DOI 10.1159/000491058↗
- Kyung Hee Jung · 7 shared papers, 2016–2022 · strength 0.58
- Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
- Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
- Paper Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. DOI 10.1159/000491058↗
- Yeo Wool Kang · 6 shared papers, 2017–2022 · strength 0.52
- Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
- Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
- Paper Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. DOI 10.1159/000491058↗
- Soon‐Sun Hong · 6 shared papers, 2016–2022 · strength 0.50
- Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
- Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
- Paper A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. DOI 10.1016/j.canlet.2018.03.041↗
- Mi Kwon Son · 5 shared papers, 2016–2022 · strength 0.43
- Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
- Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
- Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
- Ji Eun Lee · 5 shared papers, 2017–2021 · strength 0.38
- Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
- Paper Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. DOI 10.1159/000491058↗
- Paper A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. DOI 10.1016/j.canlet.2018.03.041↗
- Yong‐Sung Kim · 3 shared papers, 2018–2022 · strength 0.31
- Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
- Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
- Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
- Ji Eun Lee · 1 shared paper, 2022 · strength 0.14
- Marufa Rumman · 2 shared papers, 2016–2018 · strength 0.13
- Soon Sun Hong · 1 shared paper, 2018 · strength 0.08
- Sungwoo Hong · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.